




Cytokinetics®

# ACACIA-HCM Topline Results

May 5, 2026



# ACACIA-HCM: Phase 3 Trial of *Aficamten* in nHCM



Full results to be presented at upcoming medical meeting

| Primary Endpoints                  | Change from Baseline to Week 36<br>LSM [95% CI] |                      | <i>Aficamten</i> vs Placebo<br>LSM [95% CI] | p-value |
|------------------------------------|---|----------------------|---|---------|
|                                    | <i>Aficamten</i>                                | Placebo              |   |         |
| <b>KCCQ-CSS</b>                    | 11.4 (9.6 – 13.2)                               | 8.4 (6.6 – 10.2)     | <b>3.0 (0.5 - 5.5)</b>                      | 0.021   |
| <b>pVO<sub>2</sub> (ml/kg/min)</b> | 0.64 (0.32 – 0.95)                              | -0.03 (-0.35 – 0.28) | <b>0.67 (0.22 - 1.1)</b>                    | 0.003   |

**No new safety signals identified**

**% participants completing planned dosing:**  
Similar between groups  
(88.4% on *aficamten* vs. 90.3% on placebo)

**LVEF <50%:**  
27 (10%) on *aficamten* vs. 2 (1%) on placebo;  
2 participants on *aficamten* had a serious adverse event of HF associated with LVEF <50%

**Treatment Interruptions**  
Treatment interruptions due to LVEF <40% occurred in 3% of patients on *aficamten*

**Statistically significant (p<0.001) improvements observed in key secondary endpoints:**

1. Proportion of participants with improvements in NYHA Functional Class
2. Composite z-score of ventilatory efficiency and pVO<sub>2</sub>
3. N-terminal pro-B-type natriuretic peptide (NT-proBNP)


nHCM: non-obstructive hypertrophic cardiomyopathy; pVO<sub>2</sub>: peak oxygen uptake; LSM: least squares mean; CI: confidence interval; KCCQ-CSS: Kansas City Cardiomyopathy Questionnaire Clinical Summary Score; NYHA: New York Heart Association; CV: cardiovascular; HF: heart failure; LVEF: left ventricular ejection fraction; AE: adverse event  
MYQORZO is only approved in the U.S., China and the EU for the treatment of adults with symptomatic oHCM.

# ACACIA-HCM: Phase 3 Trial of *Aficamten* in nHCM




Robust & consistent improvements throughout treatment period

LS Mean Change from Baseline in KCCQ-CSS



Change from Baseline to Week 36 in pVO<sub>2</sub>



nHCM: non-obstructive hypertrophic cardiomyopathy; LS: least squares; KCCQ-CSS: Kansas City Cardiomyopathy Questionnaire Clinical Summary Score; LSM: least squares mean; EOT: End of Treatment; EOS: End of Study; pVO<sub>2</sub>: peak oxygen uptake  
 MYQORZO is only approved in the U.S., China and the EU for the treatment of adults with symptomatic oHCM.